GSK Pharma Q1 profit rises 16% on general medicines and vaccines growth
Key Takeaways
- •Net profit increased 16% year on year to ₹237.1 crore in the first quarter of FY27.
- •Revenue from operations rose 16.6% to ₹938 crore from ₹805 crore a year earlier.
- •Growth in the general medicines and vaccines businesses supported the quarterly performance.
- •The results suggest that demand in these segments remained a key driver for GSK Pharma during the quarter.
GSK Pharma Q1 profit rises 16% on general medicines and vaccines growth
GSK Pharma reported a 16% rise in net profit for the first quarter of FY27, with earnings supported by growth in its general medicines and vaccines businesses.
The company's net profit stood at ₹237.1 crore in the quarter, compared with ₹205 crore in the same period a year earlier. Revenue from operations increased 16.6% to ₹938 crore from ₹805 crore in the corresponding quarter last year.
The results indicate that demand in these two segments remained a key driver for the company during the quarter, alongside the broader significance of vaccines and established medicines in GSK Pharma's portfolio. For readers tracking the company, the quarter's top-line and profit growth provide a fresh benchmark for how its core business lines are contributing to performance in FY27.
Tags